Liver disease and hepatocellular carcinoma in alcoholics: The role of anticraving therapy

Current Drug Targets

Volumn 17, Issue 2, 2016, Pages 239-251

  Borro, Paolo ^a   Leone, Silvia ^a   Testino, Gianni ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Alcohol dependence; Alcoholic liver disease; Anticraving drugs; Support groups

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; ACAMPROSATE; ARIPIPRAZOLE; BACLOFEN; BENZODIAZEPINE; CLOZAPINE; DISULFIRAM; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FIBRONECTIN; GABAPENTIN; METADOXINE; NALMELFENE; NALTREXONE; ONDANSETRON; OPIATE ANTAGONIST; OXYBATE SODIUM; PREGABALIN; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SIMEPREVIR; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VARENICLINE; DRUG COMBINATION; DRUGS USED IN THE TREATMENT OF ADDICTION; PYRIDOXINE; PYROGLUTAMIC ACID; TAURINE;

ALCOHOL LIVER DISEASE; ALCOHOLISM; ARTICLE; CHRONIC ACTIVE HEPATITIS; CHRONIC HEPATITIS; DRUG DEPENDENCE; FATTY LIVER; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; META ANALYSIS (TOPIC); OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEATOSIS; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CHEMICALLY INDUCED; COMPLICATION; DRUG COMBINATION; LIVER NEOPLASMS; PSYCHOLOGY; RISK FACTOR;

ALCOHOL DETERRENTS; ALCOHOLICS; ALCOHOLISM; BACLOFEN; CARCINOMA, HEPATOCELLULAR; DRUG COMBINATIONS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; PYRIDOXINE; PYRROLIDONECARBOXYLIC ACID; RISK FACTORS; TAURINE;

EID: 84959372783     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666150518102204     Document Type: Article

References (105)

1. World Health Organization global status report on alcohol. Geneva: World Health Organization, 2006
2. Testino G, Patussi V, Leone S, Scafato E, Borro P. Moderate alcohol use and health: a nonsense. Nutr Metab Cardiovasc Dis 2014; 24: 4-5.
3. Testino G, Patussi V, Scafato E, Ancarani O, Borro P. Alcohol, cardiovascular disease and cancer. Alcohol Alcohol 2013; 48: 627-628.
4. Schutze M, Boeing H, Pischon T, et al. Alcohol attributable burden incidence of cancer in eight European countries based on results from prospectivse cohort study. BMJ 2011; 342: d1584.
5. Rehm J. The risks associated with alcohol use and alcoholism. Alcohol Res Health 2011; 34: 135-143.
6. Pessione F, Ramond MJ, Peters L. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Ef- fect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003; 23: 45-53.
7. Addolorato G, Mirijello A, Leggio L. Alcohol addiction: toward a patient-oriented pharmacological treatment. Expert Opin Pharma- cother 2013; 14: 2157-2160.
8. Testino G, Leone S, Borro P. Treatment of alcohol dependence: recent progress and reduction of consumption. Minerva Med 2014; 105: 446-447.
9. Cloninger CR, Bohman M, Sigvardsson S. Inheritance of alcohol abuse. Cross-fostering analysis of adopted men. Arch Gen Psych 1981; 38: 861-868.
10. Babor TF, Hofmann MI, DelBoca FK, et al. Types of alcoholics. Evidence for an empirically derived typology based on indicator of vulnerability and severity. Arch Gen Psychiatry 1992; 49: 599-608.
11. Lesh OM, Dietezel M, Musalek M, Walter H, Zeiler K. The course of alcoholism. Long term prognosis in different subtypes. Forensic Sci Int 1988; 36: 121-138.
12. Addolorato G, Mirijello A. Management of alcohol dependence in patients with liver disease. CNS Drugs 2013; 27: 287-299.
13. Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM. Combined pharmacotherapies and behavioural interven- tions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295: 2003-2017.
14. McCarty CA, Ebel BE, Garrison MM. Continuity of binge and harmful drinking from late adolescence to early adulthood. Pediat- rics 2004; 114: 714-719.
15. Pilling S, Yesufu-Udechuku A, Taylor C. Diagnosis, assessment, and management of harmful drinking and alcohol dependence: summary of NICE guidance. BMJ 2011; 342: 490-492.
16. Testino G. Alcoholic hepatitis. J Med Life 2013; 6: 161-167.
17. Testino G. Alcoholic diseases in hepato-gastroenterology: a point of view. Hepato-Gastroenterol 2008; 55: 371-377.
18. Grasselli E, Compalati AD, Voci A, et al. Altered oxidative stress/antioxidant status in blood alcoholic subjects is associated with alcoholic liver disease. Drug Alcohol Depend 2014; 3143: 112-119.
19. Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41: 845-850.
20. Grossi S, Sumberaz A, Gosmar M, Mattioli F, Testino G, Martelli A. DNA damage in perpheral blood lymphocytes of patients with cirrhosis related to alcohol abuse or to hepatitis B and C viruses. Eur J Gastroenterol Hepatol 2008; 20: 22-25.
21. Sung NY, Choi KS, Park EC. Smoking, alcohol and gastric cancer risk in Korean men: the National Health Insurance Corporation Study. Br J Cancer 2007; 97: 700-704.
22. Hassan MM, Hwang LY, Hatten CJ. Risks factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabete mellitus. Hepatology 2002; 36: 1206-1213.
23. European Medicine Agency. http://www.ema. Nalmelfene, This EPAR was last updated on 04/02/2014
24. Caputo F, Vignoli T, Grignaschi A, Cibin M, Addolorato G, Bernardi M. Pharmacological management of alcohol dependence: from mono-therapy to pharmacogenetics and beyond. Eur Neuro- psychopharmacol 2014; 24(2): 181-191.
25. Gaval-Cruz M, Weinshenker D. Mechanisms of disulfiram-induced cocaine abstinence. Mol Interv 2009; 9: 175-187.
26. Franck J, Jayaram-Lindstrom J. Pharmacotherapy for alcohol dependence: status of current treatments. Curr Opin Neurobiol 2013; 23: 692-699.
27. Addolorato G, Leggio L, Ferrulli A, Caputo F, Gasbarrini G. The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opin Investig Drugs 2009; 18: 1-22.
28. Leone MA, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F. Gamma-hydroxybutyrate (GHB) for treatment of alcohol with- drawal and prevention of relapses. Cochrane Database Syst Rev 2, 2010; (2): CD0066266..
29. Caputo F, Francini S, Stoppo M, et al. Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: an open comparative study. J Psycho- pharmacol 2009; 23: 883-890. <
30. Caputo F, Francini S, Brambilla R, et al. Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity. Eur Neuropsychopharmacol 2011; 21: 450-456.
31. De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate. CNS Drugs 2005; 19: 517-537.
32. Rossetti ZL, Carboni S. Ethanol withdrawal is associated with increased extracellular glutamate in the rat striatum. Eur J Pharmacol 1995; 283: 177-183.
33. Dahchour A, De Wittte P, Bolo N, et al. Central effects of acamprosate blocks the glutamate increase in the nucleo accumbens mi- crodialysate in ethanol withdrawn rats. Psychiatry Res 1998; 82: 107-114.
34. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol dependent individuals: results and meta-analysis. Alcohol Clin Exp Res 2004; 28: 51-63.
35. Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patient with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motiva- tion. J Psychiatr Res 2006; 40: 383-393.
36. Anton RF, O’Malley SS, Ciraulo DA, et al. COMBINE study research group: Combined pharmacotherapies and behavioural inter- ventions of alcohol dependence - the Combine study: a randomized controlled trial. J Am Med Assoc 2006; 295: 2003-2017.
37. Mann K, Lemenager T, Hoffmann S, et al. Results of a double blind, placebo-controlled pharmacotherapy trial in alcoholism con- ducted in Germany and comparison with the US COMBINE study. Addict Biol 2013; 18(6): 937-946.
38. Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010; (9): CD004332.
39. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 2013; 108: 275-293.
40. Verheul R, Lehert P, Geerlings PJ, Koeter MW, van den Brink W. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent pa- tients. Psychopharmacology (Berl) 2005; 178: 167-173.
41. Tolliver BK, DeSantis SM, Brown DG, Prisciandaro JJ, Brady KT. A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disor- der: a preliminary report. Bipolar Disord 2012; 14: 54-63.
42. Tek C, Srihari V, Tek E. Successful acamprosate treatment of alcohol dependence in schizophrenia. Schizophr Res 2008; 106: 373.
43. Mason BJ, Lehert P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res 2012; 3: 497-508.
44. Kiefer F, Witt SH, Frank J, et al. Involvement of the atrial natriuretic peptide transcriptor factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacoge- nomics J 2011; 11: 368-374.
45. Karpyak VM, Winham SJ, Biernacka JM, et al. Association of GATA4 sequence variation alcohol with dependence. Addict Biol 2014; 19(2): 312-315.
46. Stromberg MF, Mackler SA. A comparison of the effects of 6-beta naltrexol and naltrexone on the consumption of ethanol or sucrose using a limited access procedure in rats. Pharmacol Biochem Behav 2002; 72: 483-490.
47. Lee MC, Wager HN Jr. Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 1988; 29: 1207-1211
48. Rosner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010; (12): CD001867.
49. Oslin DW, Berrettini W, Kranzler HR. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone re- sponse in alcohol-dependent patients. Neuropsychopharmacology 2003; 28: 1546-1552.
50. Anton R. Naltrexone for the management of alcohol dependence. N Engl J Med 2008; 359: 715-721.
51. Marini V, Fucile C, Zuccoli ML, et al. Involvement of the muopioid recepto gene polymorphism A118G in the efficacy of de- toxification of alcohol dependent patients. Addict Behav 2013; 38: 1669-1671.
52. Volpicelli JR, Rhines KC, Rhines JS. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997; 54: 737-742.
53. Bartus RT, Emerich DF, Hotz J. Vivitrex, an injectable extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamics evidence of efficacy for 1 month in rats. Neu- ropsychopharmacology 2003; 28: 1973-1982.
54. Rolland B, Karila L, Guardia D, Cottencin O. Pharmacological approaches of binge drinking. Curr Pharml Des 2011; 17: 1333-1342.
55. Crews FT, Boettiger CA. Impulsivity, frontal lobes and risk for addiction. Pharmacol Biochem Behav 2009; 93: 237-247.
56. Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind placebo controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 1994; 18: 1162-1167.
57. Karhuvaara S, Simojoki K, Virta A, et al. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Al- cohol Clin Exp Res 2007; 31: 1179-1187.
58. Mann K, Bladstrom A, Troup L. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry 2013; 73: 706-713.
59. Gual A, He Y, Torup L. A randomized, double-blind, placebo controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol 2013; 23(11): 1432-1442.
60. Calabrese V, Bombaci G, Calderone A, Rizza V. Effects of meta-doxine on cellular free fatty acid levels in ethanol treated rats. Int J Tiss React 1993; 15: 235-243.
61. Shpilenya LS, Muzychenco AP, Gasbarrini G, Addolorato G. Metadoxine in acute alcohol intoxication: a double-blind, random- ized, placebo-controlled study. Alcohol Clin Exp Res 2002; 26: 340-346.
62. Diaz Martinez MC, Diaz Martinez A, Villamil Salcedo V, Cruz Fuentes C. Efficacy of metadoxine in the management of acute al- cohol intoxication. J Int Med Res 2002; 30: 44-51
63. Leggio L, Kenna GA, Ferrulli A, et al. Preliminary findings of metadoxine for the treatment of alcohol dependence and alcoholic disease. Hum Psychopharmacol Clin Exp 2011; 26: 554-559.
64. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol- dependent patients with liver cirrhosis: randomized, double-blind controlled study. Lancet 2007; 370: 1915-1920.
65. Muzyk AJ, Rivelli SK, Gagliardi JP. Defining the role of baclofen for the treatment of alcohol dependence: a sistematic review of the evidence. CNS Drugs 2012; 26: 69-78.
66. Addolorato G, Caputo F, Capristo E. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002; 37: 504-508.
67. Dore GM, Lo K, Juckes L, Bezyan S, Latt N. Clinical experience with baclofen in the management of alcohol-dependent patients with psychiatric comoebidity: a selected case series. Alcohol Alcohol 2011; 46: 714-720.
68. Caputo F, Vassallo G, Pappas G, et al. Pharmacological treatment of alcoholdependence. Alcologia 2012; 14: 1120.
69. Johnson BA, Ait-Daud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 2003; 361: 1677-1685.
70. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298: 1641-1651.
71. Amini M, Runyon BA. Alcoholic hepatitis: a clinician’s guide to diagnosis and therapy. World J Gastroenterol 2010; 16: 4905-4912.
72. Addolorato G, Mirijello A, Leggio L, Ferrulli A, Landolfi R. Management of alcohol dependence in patients with liver disease. CNS Drugs 2013; 27: 287-299.
73. Soderpalm B, deBejczy A, Ericson M, et al. The ethanol nAChR interaction and its relevance for modulating ethanol consumption in rodents and man. Alcohol Clin Exp Res 2012; S202.
74. Mitcell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL. Varenicline decreases alcohol consumption in heavy-drinking smok- ers. Psychopharmacology (Berl) 2012; 223: 299-306.
75. Falk DE, Castle IJ, Ryan M, Ferting J, Litten RZ. Moderators of varenicline treatment effects in a double-blind, placebo-controlled trial for alcohol dependence: an exploratory results. J Addict Med 2015; 9: 296-303
76. Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Field HL. Varenicline decreases alcohol consumption in heavy-drinking smok- ers. Psychopharmacology 2012; 223: 299-306.
77. Litten RZ, Ryan ML, Fertig JB, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med 2013; 7: 277-286.
78. Kranzler HR, Covault J, Feinn R, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psy- chiatry 2014; 171: 445-452.
79. Johnson BA, Roache JD, Javors MA, et al. Ondasentron for reduction of drinking among biologically predisposed alcoholic patients. A randomized controlled trial. JAMA 2000; 284: 963-971.
80. Johnson BA, Seneviratne C, Wang XQ, Ait-Daoud N, Li MD. Determination of genotype combinations that can predict the out- come of the treatment of alcohol dependence using the 5-HT(3) an- tagonist ondansetron. Am J Psychiatry 2013; 170: 1020-1031.
81. Mason BJ, Quello S, Goodell V, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence. A randomized clinical trial. JAMA Intern Med 2014; 174(1): 70-77.
82. Caputo F, Bernardi M. Medications acting on the GABA system in the treatment of alcohol dependence: a review. Curr Pharm Des 2011; 17: 1323-1332.
83. Di Nicola M, Martinetti G, Tedeschi D, et al. Pregabalin in outpatients detoxification of subject with mild-to-moderate alcohol with- drawal syndrome. Hum Psychopharmacol 2010; 25: 268-275.
84. Brookwell L, Hogan C, Healy D, Mangin D. Ninety-three cases of alcohol dependence following SSRI treatment. Int J Risk Safety Med 2014; 26: 99-107.
85. Curzio O, Tilli A, Mezzasalma L. Characteristics of alcoholics attending “clubs of alcoholics in treatment” in Italy: a national sur- vey. Alcohol Alcohol 2012; 47: 317-321.
86. Testino G, Borro P. Liver transplantation and severe acute alcoholic hepatitis: an ethical consideration. J Hepatol 2014; 61(3): 706-707.
87. Testino G, Borro P. Alcoholic hepatitis and liver transplantation: is an abstinence of six month necessary? Hepato-Gastroenterol 2012; 59: 4.
88. McCrady BS, Owens MD, Borders AZ, Brovko JM. Psychosocial approaches to alcohol use disorders since 1940: a review. J Stud Alcohol Drugs 2014; 75 (Suppl 17): 68-78.
89. Ait-Daoud N, Johnson BA, Prihoda TJ, Hargita ID. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence. Psycho- pharmacol 2001; 154: 23-27.
90. Anton RF, MyrichH, Wright TM, et al. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry 2011; 168: 709-717.
91. Batki SL, Pennington DL. Toward personalized medicine in the pharmacotherapy of alcohol use disorder: targeting patient genes and patient goals. Am J Psychiatry 2014; 4: 391-394.
92. Addolorato G, Leggio L, Ferrulli A. The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risk and benefits. A focus on clinical data. Expert Opin Investig Drugs 2009; 18: 675-686.
93. Skala K, Caputo F, Mirijello A, et al. Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syn- drome to the alcohol relapse prevention. Expert Opin Pharmacother 2014; 15(2): 245-257.
94. Delgrange T, Khater J, Capron D. Effect of acute administration of acamprosate on the risk of encephalopathy and on arterial pressure in patients with alcoholic cirrhosis. Gastroenterol Clin Biol 1992; 16: 687-691.
95. Addolorato G, Mirijello A, Leggio L, et al. Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. Alcohol Clin Exp Res 2013; 37: 1601-1608.
96. Cuadrado A, Fabrega E, Casafont F. Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation 2005; 11: 420-426.
97. Altamirano J, Bataller R, Cardenas A. Predictive factors of abstinence in patients undergoing liver transplantation for alcoholic liver disease. Annals of Hepatology 2012; 11: 213-221.
98. Mathurin P, Moreno C, Samuel D. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365: 1790-1800.
99. Burroughs AK. Liver transplantation for severe alcoholic hepatitis saves lives. J Hepatol 2012; 57(2): 451-452.
100. Shiffman ML, Long AG, James A, Alexander P. My treatment approach to chronic hepatitis C virus.. Mayo Clin Proc 2014; 89: 934-942.
101. Borro P, Scudelletti M, Testino G. Treatment of alcoholic very early hepatocellular carcinoma: role of percutaneous ablation. Be- yond Barcellona criteris. Minerva Chir 2014; 69: 57-58.
102. Testino G, Burra P, Bonino F, et al. Acute alcoholic hepatitis, end stage alcoholic liver disease and liver transplantation: an Italian po- sition statement. World J Gastroenterol 2014; 20: 14642-14651.
103. Borro P, Testino G. Surveillance for hepatocellular carcinoma in alcoholic patients. Am J Gastroenterol 2013; 108: 1811.
104. Borro P, Testino G. Contrast-enhanced ultrasound for focal liver lesions. Is it necessary an hepatologist expert in ultrasound tech- niques in the third millennium? Liver Int 2013; 33: 1609-1610.
105. Abenavoli L, Milic N, Rouabhia S, Addolorato G. Pharmacother- apy of acute alcoholic hepatitis in clinical practice. World J Gastro- enterol 2014; 20: 2159-2167.